Date: 2012-06-05
Type of information: Grant
Company: Erytech Pharma (France)
Investors: OSEO (France)
Amount: € 6.95 million
Funding type: grants and redeemable advances
Planned used: these funds will be used to lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy). The consortium also includes Exonhit, InGen BioSciences, AP-HP (Paris Public Hospitals), Inserm (National Institute for medical research), and Paris-Diderot University. It aims at developing innovative therapies for the enzymatic treatment of chemo- or radio-resistant cancers, and accompanying tools to identify responders and enable personalized care of patients. The project, endorsed by the Competitiveness Cluster Lyonbiopôle, will run over 8 years. The total amount of support awarded to the consortium amounts to approximately €10.7 million.
Others: ERYTECH Pharma, a late-stage French biopharmaceutical company developing medicinal products for oncology, has received a total of € 6.95 million in support from the Strategic Industrial Innovation program of the French public organization OSEO lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy).
The company is developing a new approach to fight cancer by starving tumors through depleting specific amino acids, needed for the tumor growth, from their metabolic environment. Weakening tumors by acting on their environment is synergic with classical chemotherapy drugs
Major goals of this project are:
• To develop a relevant ex vivo human tumor model in order to be as close as possible to the clinical conditions
• To offer to clinicians an adjusted therapy according to patients’ tumor characteristics
• To identify biomarkers of susceptibility to therapeutic response in the context of reducing the risks associated with the development of treatments
• To develop an enzymatic therapy companion diagnostic that will identify responders, thus improving personalized care
• To propose a new monitoring test that enables the simple, rapid, and reliable measure to check therapeutic enzymes action in real time during the treatment.
Therapeutic area: Cancer - Oncology
